TRANSVAC: new vaccines faster

Welcome to TRANSVAC, a collaborative infrastructure project funded under the European Commission’s (EC) 7th Framework Programme (FP7). The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance European research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe.

In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On this website you can find out about how to benefit from TRANSVAC’s portfolio of activities, learn how to apply for access to the TRANSVAC’s high-quality Infrastructure Free Services and Paid Services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is done by the European Vaccine Development Stakeholder Working Groups.

News

13 August 2015

MVVC/MVVC 2 collaborator receives ASTMH 2015 Annual Meeting Travel Award

Muhammed Afolabi (MRC Gambia) received an ASTMH 2015 Annual Meeting Travel Award that is supported in part by the Bill & Melinda Gates Foundation.

06 August 2015

WHO-CC Vaccine Pharmacovigilance Fellowship 7th-18th September

The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance is delighted to announce to you its maiden Vaccine Pharmacovigilance Fellowship Programme.  Deadline for registration is 21st August 2015.  For enquiries kindly contact us at training [at] who-pvafrica [dot] org

24 July 2015

First Malaria vaccine with positive scientific opinion from the European Medicines Agency (EMA)

EVI congratulates GlaxoSmithKline and PATH Malaria Vaccine Initiative (MVI) on their resounding success on the development of MosquirixTM, also known as RTS,S, for use in children aged six weeks to 17 months.